These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 33108917

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Antitumor activity of a pexidartinib bioisostere inhibiting CSF1 production and CSF1R kinase activity in human hepatocellular carcinoma.
    Awasthi BP, Guragain D, Chaudhary P, Jee JG, Kim JA, Jeong BS.
    Chem Biol Interact; 2023 Jan 05; 369():110255. PubMed ID: 36368339
    [Abstract] [Full Text] [Related]

  • 7. The c.1085A>G Genetic Variant of CSF1R Gene Regulates Tumor Immunity by Altering the Proliferation, Polarization, and Function of Macrophages.
    Yeh YM, Hsu SJ, Lin PC, Hsu KF, Wu PY, Su WC, Chang JY, Shen MR.
    Clin Cancer Res; 2017 Oct 15; 23(20):6021-6030. PubMed ID: 28724665
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. c-FMS inhibitors: a patent review.
    Burns CJ, Wilks AF.
    Expert Opin Ther Pat; 2011 Feb 15; 21(2):147-65. PubMed ID: 21204725
    [Abstract] [Full Text] [Related]

  • 11. Clinical evaluation of colony-stimulating factor 1 receptor inhibitors.
    Ordentlich P.
    Semin Immunol; 2021 Apr 15; 54():101514. PubMed ID: 34776301
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. CSF1R inhibitors are emerging immunotherapeutic drugs for cancer treatment.
    Wen J, Wang S, Guo R, Liu D.
    Eur J Med Chem; 2023 Jan 05; 245(Pt 1):114884. PubMed ID: 36335744
    [Abstract] [Full Text] [Related]

  • 16. CSF1R Is Required for Differentiation and Migration of Langerhans Cells and Langerhans Cell Histiocytosis.
    Lonardi S, Scutera S, Licini S, Lorenzi L, Cesinaro AM, Gatta LB, Castagnoli C, Bollero D, Sparti R, Tomaselli M, Medicina D, Calzetti F, Cassatella MA, Facchetti F, Musso T, Vermi W.
    Cancer Immunol Res; 2020 Jun 05; 8(6):829-841. PubMed ID: 32238382
    [Abstract] [Full Text] [Related]

  • 17. A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model.
    Ohno H, Kubo K, Murooka H, Kobayashi Y, Nishitoba T, Shibuya M, Yoneda T, Isoe T.
    Mol Cancer Ther; 2006 Nov 05; 5(11):2634-43. PubMed ID: 17121910
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.